These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

100 related articles for article (PubMed ID: 3718405)

  • 1. [Procedures for the isolation and characterization of human antithrombin III].
    Trobisch H; Wüst T; Rustige H
    Behring Inst Mitt; 1986 Feb; (79):177-90. PubMed ID: 3718405
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Isolation and characterization of a coagulation factor Xa inhibitor from black fly salivary glands.
    Jacobs JW; Cupp EW; Sardana M; Friedman PA
    Thromb Haemost; 1990 Oct; 64(2):235-8. PubMed ID: 2270532
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Biochemical and functional study of antithrombin III in newborn infants.
    McDonald MM; Hathaway WE; Reeve EB; Leonard BD
    Thromb Haemost; 1982 Feb; 47(1):56-8. PubMed ID: 7071806
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Covalent complexes between low molecular weight heparin fragments and antithrombin III - inhibition kinetics and turnover parameters.
    Hoylaerts M; Holmer E; de Mol M; Collen D
    Thromb Haemost; 1983 Apr; 49(2):109-15. PubMed ID: 6868006
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The effect of a sulfated polysaccharide on antithrombin III.
    Czapek EE; Kwaan HC; Szczecinski M
    J Lab Clin Med; 1980 Jun; 95(6):783-90. PubMed ID: 6155418
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Purification and characterization of hereditary abnormal antithrombin III with impaired thrombin binding.
    Jørgensen M; Petersen LC; Thorsen S
    J Lab Clin Med; 1984 Aug; 104(2):245-56. PubMed ID: 6747440
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Antithrombin III binding to surface immobilized heparin and its relation to F Xa inhibition.
    Kodama K; Pasche B; Olsson P; Swedenborg J; Adolfsson L; Larm O; Riesenfeld J
    Thromb Haemost; 1987 Dec; 58(4):1064-7. PubMed ID: 3481885
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The molecular-weight dependence of the rate-enhancing effect of heparin on the inhibition of thrombin, factor Xa, factor IXa, factor XIa, factor XIIa and kallikrein by antithrombin.
    Holmer E; Kurachi K; Söderström G
    Biochem J; 1981 Feb; 193(2):395-400. PubMed ID: 6914196
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Decreased heparin sensitivity of cyclohexanedione-modified factor Xa.
    Blaskó G; Machovich R
    Thromb Haemost; 1979 Aug; 42(2):556-63. PubMed ID: 505364
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Abnormal properties and behaviors of antithrombin III found in a thrombophilic patient: defective biological functions and dissimilar antigenic determinants.
    Murayama H; Matsuda M
    Thromb Haemost; 1986 Oct; 56(2):165-71. PubMed ID: 3101219
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Heterogeneity of mammalian antithrombin III].
    Bashkov GV; Kalishevskaia TM; Strukova SM
    Biokhimiia; 1989 Nov; 54(11):1797-803. PubMed ID: 2627551
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Homozygous variant of antithrombin III: AT III Fontainebleau.
    Boyer C; Wolf M; Vedrenne J; Meyer D; Larrieu MJ
    Thromb Haemost; 1986 Aug; 56(1):18-22. PubMed ID: 3775688
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Heparin, its fractions, fragments and derivatives. Some newer perspectives.
    Fareed J
    Semin Thromb Hemost; 1985 Jan; 11(1):1-9. PubMed ID: 3919446
    [TBL] [Abstract][Full Text] [Related]  

  • 14. High and low anticoagulant activity heparins. Preparation in large scale and degree of complexation with antithrombin III.
    Takahashi HK; Nader HB; Dietrich CP
    Arzneimittelforschung; 1985; 35(11):1620-3. PubMed ID: 4091864
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Conformational conversion of antithrombin to a fully activated substrate of factor Xa without need for heparin.
    Huntington JA; Gettins PG
    Biochemistry; 1998 Mar; 37(10):3272-7. PubMed ID: 9521646
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Expression, purification, and characterization of recombinant human factor X.
    Rudolph AE; Mullane MP; Porche-Sorbet R; Miletich JP
    Protein Expr Purif; 1997 Aug; 10(3):373-8. PubMed ID: 9268685
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The inhibition of the anticoagulant activity of heparin by platelets, brain phospholipids, and tissue factor.
    Ofosu FA; Cerskus AL; Hirsh J; Smith LM; Modi GJ; Blajchman MA
    Br J Haematol; 1984 Jun; 57(2):229-38. PubMed ID: 6733045
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Neutralization and binding of heparin by S protein/vitronectin in the inhibition of factor Xa by antithrombin III. Involvement of an inducible heparin-binding domain of S protein/vitronectin.
    Preissner KT; Müller-Berghaus G
    J Biol Chem; 1987 Sep; 262(25):12247-53. PubMed ID: 2442161
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The characteristics of anticoagulation by covalently immobilized heparin.
    Miura Y; Aoyagi S; Kusada Y; Miyamoto K
    J Biomed Mater Res; 1980 Sep; 14(5):619-30. PubMed ID: 7349668
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Inhibition of activated coagulation factor VII by normal human plasma.
    Dahl PE; Abildgaard U; Larsen ML; Tjensvoll L
    Thromb Haemost; 1982 Dec; 48(3):253-6. PubMed ID: 7164015
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.